What is Pancreatic Cancer?
Most people with pancreatic cancer have a type called Pancreatic Ductal Adenocarcinoma (PDAC). It is one of the deadliest cancers because it often spreads before it's found and grows aggressively.
Only about 10–15% of people are diagnosed early enough for surgery, which is the only chance of a cure, many sadly have cancer that is too advanced or has already spread.
How is Pancreatic Cancer Treated?
🏥 Surgery
🩻 Staging
There are four main stages:
Doctors also look at tumour biology (blood markers like CA 19-9) and the patient’s overall health.
💊 Chemotherapy
🔬 Radiation Therapy
What If Surgery Is Not an Option?
For many patients, surgery is not possible because the cancer has spread or is in a location that makes it dangerous to operate. In these cases, treatment focuses on improving quality of life and extending survival using:
Newer Treatments and Hope for the Future
🧬 Targeted Therapy
🛡️ Immunotherapy
🧪 Clinical Trials
Outlook and Support
While pancreatic cancer remains a very serious disease, treatment options have improved in recent years. The best care often comes from specialist centers like ours at Royal Stoke Hospital where experts from different fields work together.
Patients and families should always feel comfortable asking about:
Critical Analysis of Key Studies
There is an ongoing debate within the Pancreatic Surgery Community about the timing of chemotherapy (and radiotherapy) in the management of patients with so-called borderline resectable disease. This is where the tumour has grown so that it is contact with major veins or arteries. In some centres, patients are sent for chemotherapy and sometimes radiotherapy prior to surgery (neoadjuvant chemotherapy) and in other centres, patients have surgery first followed by chemotherapy (adjuvant chemotherapy).
High quality evidence from studies such as the PREOPANC trials have underscored the importance of neoadjuvant therapy in improving outcomes for borderline resectable pancreatic cancer patients. PREOPANC-1 established the survival benefit of preoperative chemoradiation, especially for long-term survival. PREOPANC-2 further explored regimen optimization but showed no survival advantage for intensive chemotherapy over chemoradiation. Together, these trials support multidisciplinary, individualized treatment planning, and reinforce the growing role of neoadjuvant strategies in pancreatic cancer management. They are not however without flaws and ongoing trials such as PREOPANC-3 and Alliance A021806 will further clarify the role and timing of perioperative FOLFIRINOX.
What is key is that your clinician treats you as an individual and takes a whole host of factors into account. Many of these trials were carried out in different healthcare systems with different patient populations, where chemotherapy can be started promptly. Timely diagnostics, coordinated care pathways, and minimising delays between diagnosis and therapy initiation remain key challenges, particularly in health systems like the NHS where procedural backlogs can compromise early treatment initiation.
I have created a helpful summary highlighting the key points from each study as well as issues and take-home messages
Salop Health Ltd
Copyright © 2025 Salop Health Ltd - All Rights Reserved.